Failure to Act on Consultant Pharmacist Medication Review Recommendations
Summary
The facility failed to ensure that physician review and action occurred in a timely manner on medication regimen review irregularities identified by the consultant pharmacist for two residents. One resident had diagnoses including dementia with psychotic disturbance, depression, pain in the right hip, and anxiety disorder, and was receiving escitalopram 20 mg at bedtime and hydrocodone/acetaminophen 5-325 mg, 0.5 tablet as needed. The consultant pharmacist identified that escitalopram did not appear to be showing behaviors to support continued use at the current dose, recommended considering a gradual dose reduction to 10 mg daily with the goal of discontinuance, and suggested changing the administration time to daytime. The consultant pharmacist also recommended clarifying hydrocodone/acetaminophen MAR instructions by adding a respiratory rate hold parameter and documenting respiratory rate on the MAR. For that same resident, the record review showed severe impairment in cognitive skills for daily decision making, partial/moderate assistance with some activities of daily living, scheduled pain medication use, and no mood or behavior symptoms documented on the December MAR. During interview, the LVN stated the DON was responsible for the medication regimen review and that neither physician notification nor changes related to the consultant pharmacist’s recommendations were documented. The DON stated there was no specific time frame for completing the medication regimen review, that it should at least be completed within the month, and that follow-up was needed to see whether the physician agreed with the consultant pharmacist’s recommendations. The facility policy stated recommendations are to be acted upon and documented by facility staff and/or the prescriber, and that the physician accepts and acts upon the suggestion or rejects it with an explanation by the next physician visit. A second resident had diagnoses including dementia, depression, anxiety, and impulse disorder, with severe impairment in cognitive skills for daily decision making and no mood or behavior symptoms documented. The resident was ordered lorazepam 0.25 mg in the afternoon for anxiety and lorazepam 1 mg in the evening for anxiety. The consultant pharmacist recommended considering a dose reduction by discontinuing the afternoon dose or decreasing the evening dose to 0.5 mg, and asked that if a gradual dose reduction was contraindicated, the reason be specified. The DON stated the medication regimen review with the gradual dose reduction recommendation was not addressed by the resident’s primary care physician and that the recommendation should have been reported within a week, while the facility policy stated recommendations are to be acted upon and documented by facility staff and/or the prescriber and that the physician accepts, acts upon, or rejects the suggestion with an explanation by the next physician visit.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.